Neion Bio
Egg-based biologics manufacturing using genetic engineering and the Raptor platform.
The Company
Neion Bio uses genetic engineering to direct production of complex proteins into chicken eggs through its Raptor platform. The company is pursuing biologics, biosimilars, reagents, and animal-health applications.
In June 2026, Neion announced an oversubscribed $23 million Series A led by Caffeinated Capital. It said the financing followed emergence from stealth and a commercial co-development and supply agreement with a major pharmaceutical company.
Why It Matters
Biologics manufacturing is expensive and capacity constrained. Neion's egg-based approach is a distinctive attempt to lower cost and shorten iteration cycles, but its value depends on scientific validation, regulatory progress and real commercial supply.
Valuation History
- Raised $23M · valuation undisclosed→Jun 2026Series ASource ↗
What Changed
Profile reviewed against available public information.
THE NEXT COMPANY. A CLEARER PICTURE.
Get the next breakdown.
Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.